Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?

• DOI: 10.1007/s13539-014-0145-y
• Publication Date: 2014-04-16T11:37:37Z
• Authors: David R. Fogelman; Holly Holmes; Khalil Mohammed; Matthew H. G. Katz; Carla M. Prado; Jessica Lieffers; Naveen Garg; Gauri R. Varadhac...; Rachna Shroff; Michael J. Overman; Christopher Garrett; Robert A. Wolff; Milind Javle
• Keywords: 0301 basic medicine; 03 medical and health sciences; Original Article; 3. Good health

IGF-1 plays a role in the growth of multiple tumor types, including pancreatic cancer. also serves as factor for muscle. The impact therapeutic targeting on muscle mass is unknown.We evaluated at L3 patients enrolled randomized phase II study MK-0646 (M), monoclonal antibody directed against protein, with metastatic cancer (MPC). Two different doses M were tested, 5 and 10 mg/kg. We used Slice-o-matic (ver 4.3) software to segregate CT images into fat components measured area (cm(2)) baseline after 2 4 months treatment. Patients received either gemcitabine erlotinib (G + E), G E M, or M. Differences between groups compared using t tests.Fifty-three had both 2-month imaging available analysis. Of these, 42 their chemo, 11 only. After treatment, demonstrated decrease mass. lost 5.6 % mass; 9.1 8.6 treatment mg/kg, respectively (p = 0.53). demonstrating response less (median 4.6 %) than those stable disease (9.6 progressive (8.9 %, p 0.14). Muscle retention from imaging, defined loss <6 cm(2) muscle, correlated better survival (HR 0.51, 0.03).MPC can be expected lose even while having clinical benefit (PR SD) chemotherapy. risk drop-out death. There was non-significant trend toward greater anti-IGF-1R therapy. However, it unclear if this translates functional differences patients.